Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Lorusso

Showing results (171-180 of 280) with videos related to

Pageof 28
Sort By:
Anti-Cancer Drugs|May 29, 2015
Phase I dose-escalation study of cabazitaxel administered in combination with gemcitabine in patients with metastatic or unresectable advanced solid malignanciesOlivier Rixe, Igor Puzanov, Patricia M LoRusso, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 21, 2008
Phase I and pharmacokinetic study of lapatinib and docetaxel in patients with advanced cancerPatricia M LoRusso, Suzanne F Jones, Kevin M Koch, et al.
Journal for Immunotherapy of Cancer|September 27, 2018
Dose escalation results from a first-in-human, phase 1 study of glucocorticoid-induced TNF receptor-related protein agonist AMG 228 in patients with advanced solid tumorsBen Tran, Richard D Carvajal, Aurelien Marabelle, et al.
Investigational New Drugs|February 17, 2015
First-in-human phase 1 study of filanesib (ARRY-520), a kinesin spindle protein inhibitor, in patients with advanced solid tumorsPatricia M LoRusso, Priscila H Goncalves, Lindsay Casetta, et al.
The Lancet. Oncology|February 11, 2021
SARS-CoV-2 vaccination and phase 1 cancer clinical trialsTimothy A Yap, Lillian L Siu, Emiliano Calvo, et al.
Neuronal Signaling|June 19, 2023
Maternal immune activation and role of placenta in the prenatal programming of neurodevelopmental disordersRebecca M Woods, Jarred M Lorusso, Jennifer Fletcher, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 8, 2010
Safety, efficacy, pharmacokinetics, and pharmacodynamics of the combination of sorafenib and tanespimycinUlka N Vaishampayan, Angelika M Burger, Edward A Sausville, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 26, 2018
Phase 0 Trial of AZD1775 in First-Recurrence Glioblastoma PatientsNader Sanai, Jing Li, Julie Boerner, et al.
Frontiers in Genetics|July 26, 2018
Network Rewiring in Cancer: Applications to Melanoma Cell Lines and the Cancer Genome Atlas PatientsKuan-Fu Ding, Darren Finlay, Hongwei Yin, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 18, 2011
Phase I, dose-escalation trial of the oral cyclin-dependent kinase 4/6 inhibitor PD 0332991, administered using a 21-day schedule in patients with advanced cancerKeith T Flaherty, Patricia M Lorusso, Angela Demichele, et al.
Pageof 28

Showing results (171-180 of 280) with videos related to

Sort By:
Pageof 28
Anti-Cancer Drugs|May 29, 2015
Phase I dose-escalation study of cabazitaxel administered in combination with gemcitabine in patients with metastatic or unresectable advanced solid malignanciesOlivier Rixe, Igor Puzanov, Patricia M LoRusso, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 21, 2008
Phase I and pharmacokinetic study of lapatinib and docetaxel in patients with advanced cancerPatricia M LoRusso, Suzanne F Jones, Kevin M Koch, et al.
Journal for Immunotherapy of Cancer|September 27, 2018
Dose escalation results from a first-in-human, phase 1 study of glucocorticoid-induced TNF receptor-related protein agonist AMG 228 in patients with advanced solid tumorsBen Tran, Richard D Carvajal, Aurelien Marabelle, et al.
Investigational New Drugs|February 17, 2015
First-in-human phase 1 study of filanesib (ARRY-520), a kinesin spindle protein inhibitor, in patients with advanced solid tumorsPatricia M LoRusso, Priscila H Goncalves, Lindsay Casetta, et al.
The Lancet. Oncology|February 11, 2021
SARS-CoV-2 vaccination and phase 1 cancer clinical trialsTimothy A Yap, Lillian L Siu, Emiliano Calvo, et al.
Neuronal Signaling|June 19, 2023
Maternal immune activation and role of placenta in the prenatal programming of neurodevelopmental disordersRebecca M Woods, Jarred M Lorusso, Jennifer Fletcher, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 8, 2010
Safety, efficacy, pharmacokinetics, and pharmacodynamics of the combination of sorafenib and tanespimycinUlka N Vaishampayan, Angelika M Burger, Edward A Sausville, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 26, 2018
Phase 0 Trial of AZD1775 in First-Recurrence Glioblastoma PatientsNader Sanai, Jing Li, Julie Boerner, et al.
Frontiers in Genetics|July 26, 2018
Network Rewiring in Cancer: Applications to Melanoma Cell Lines and the Cancer Genome Atlas PatientsKuan-Fu Ding, Darren Finlay, Hongwei Yin, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 18, 2011
Phase I, dose-escalation trial of the oral cyclin-dependent kinase 4/6 inhibitor PD 0332991, administered using a 21-day schedule in patients with advanced cancerKeith T Flaherty, Patricia M Lorusso, Angela Demichele, et al.
Pageof 28